|
IL249658A0
(en)
|
|
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
IL259017A
(en)
|
|
Targeted cancer therapy
|
|
CL2018000813A1
(en)
|
|
Antibody-pyrrolobenzodiazepine drug conjugates and methods of use.
|
|
DK3294770T3
(en)
|
|
Therapeutic and diagnostic methods for cancer
|
|
DK3283527T3
(en)
|
|
COMBINATION THERAPY AGAINST CANCER
|
|
DK3331915T3
(en)
|
|
IMMUNE CHECKPOINT INHIBITORS FOR USE FOR THE TREATMENT OF BLOOD-CARRIED CANCER
|
|
DK3212670T3
(en)
|
|
COMBINATION THERAPY AGAINST CANCER
|
|
DK3283106T3
(en)
|
|
Therapeutic antibodies and uses thereof
|
|
BR112017002511A2
(en)
|
|
therapeutic pad systems and methods
|
|
DK3423087T3
(en)
|
|
Combination therapy against cancer
|
|
DK3277842T3
(en)
|
|
METHODS OF TREATING CANCER PATIENTS WITH FARCYL-TRANSFERASE INHIBITORS
|
|
BR112017011771A2
(en)
|
|
methods and compositions for cancer treatment
|
|
DK3262066T4
(en)
|
|
GENE THERAPY
|
|
DK3107563T3
(en)
|
|
GLYCOM TARGETED THERAPEUTIC AGENTS
|
|
KR20180084772A
(en)
|
|
Combination Therapy for Cancer Treatment
|
|
MX2015011899A
(en)
|
|
Methods of treating cancer and preventing cancer drug resistance.
|
|
BR112018005409A2
(en)
|
|
glycodirectional therapy.
|
|
DK4119569T3
(en)
|
|
Conjugated antisense compounds for use in therapy
|
|
DK3380086T3
(en)
|
|
CYP26-RESISTANT RAR-ALPHA-SELECTIVE AGONISTS IN CANCER TREATMENT
|
|
DK3374497T3
(en)
|
|
MODIFIED MACROPHAGE FOR USE IN THE TREATMENT OF CANCER
|
|
DK3253800T3
(en)
|
|
Prostate antigen standards and use thereof
|
|
DK3393478T3
(en)
|
|
combination therapy
|
|
DK3253208T3
(en)
|
|
Combination therapies for use in the treatment of breast cancer
|
|
IL255530A
(en)
|
|
Efflux-pump inhibitors and therapeutic uses thereof
|
|
DK3408265T3
(en)
|
|
THERAPEUTIC RELATIONS
|